Latest

21:47
[ HOME CONTROL (01747.HK): Issues Follow-up Announcement on HKEX Disciplinary Action, Says All Current Directors Appointed After Relevant Events and Compliance Adviser Engaged ] On 8 September 2026, Home Control International Limited (01747.HK) issued a voluntary announcement providing follow-up information on the HKEX disciplinary action, reiterating that the sanctions apply only to the company and two former directors; it disclosed that the controlling shareholder changed from NHPEA IV to Meta-Wisdom Tech Limited in June 2025 and all current directors were appointed after the relevant events, and that the company has voluntarily engaged a compliance adviser to strengthen internal controls and compliance.
Tag： HOME CONTROL01747.HKDisciplinary Action
21:42
[ Excelland Robotics (03231.HK): Public Offer 140.02x Subscribed, Offer Price Set at HKD 14.45, Trading to Commence Tomorrow ] On 8 September 2026, Excelland Robotics (Wuxi) Co., Ltd. (03231.HK) published its allotment results, fixing the offer price at HKD 14.45 per share with trading to commence on 9 September 2026; the Hong Kong public offer was subscribed 140.02 times without triggering clawback, the international offering was subscribed 0.99 times, net proceeds were approximately HKD 576.6 million, and issued shares after listing total 416,368,421.
Tag： Excelland Robotics03231.HKListingIPO
21:29
[ HBM HOLDINGS-B (02142.HK): Positive Phase II Interim Results for HBM9378/WIN378 in Asthma; Phase III Initiated ] On 8 September 2026, HBM Holdings Limited (02142.HK) announced in a voluntary announcement that collaborator Windward Bio had reported positive interim results from the Phase II part of POLARIS-1 for anti-TSLP antibody HBM9378/WIN378 in asthma: at week 24, the placebo-adjusted mean increase in FEV1 reached up to 256 mL (p=0.033), with FeNO down 43% and EOS down 51%, and a half-life of up to 75 days supporting twice-yearly dosing; the Phase III part has been initiated, with POLARIS-2 planned for the first half of 2027.
Tag： HBM HOLDINGS-B02142.HKR&D Progress
21:27
[ CHINASOFT INT'L (00354.HK): Wins Project for Pan-home Furnishing OpenHarmony AI Innovation Centre Worth Approximately RMB 35.5 Million ] On 8 September 2026, ChinaSoft International Limited (00354.HK) announced in a voluntary announcement that it had won the bid for the Pan-home Furnishing OpenHarmony AI Innovation Centre project under the Guangdong Industrial Robots and Smart Home Application Empowerment Centre, with a contract value of approximately RMB 35.5 million; leveraging its Xi'an OpenHarmony adaptation centre experience, the group will build big data, all-domain intelligent interconnection and digital intelligence empowerment platforms in Foshan to expand into edge intelligence and spatial intelligence.
Tag： CHINASOFT INT00354.HKwon the bid
21:22
[ AMCO UNITED (00630.HK): Sells Entire Stake in BFB Health for Approximately HKD 10.56 Million, Expected Gain of about HKD 6.4 Million ] On 8 September 2026, AMCO United Holding Limited (00630.HK) announced the disposal of 24,556,500 shares of BFB Health Limited (00205.HK) to BFB Group Limited for a total consideration of approximately HKD 10,559,000 (approximately HKD 0.43 per share), after which it holds no BFB Health shares; the disposal constitutes a discloseable transaction, with an expected gain of approximately HKD 6.4 million subject to audit, and proceeds to be used for working capital and other purposes.
Tag： AMCO UNITED00630.HKDisposal of Assets
21:19
[ SKB BIO (06990.HK): Positive Phase II Interim Results for SKB378/WIN378 in Asthma; Phase III Initiated ] On 8 September 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) announced in a voluntary announcement that collaborator Windward Bio had reported positive interim results from the Phase II part of POLARIS-1 for anti-TSLP antibody SKB378/WIN378 in asthma (147 patients enrolled): at week 24, the placebo-adjusted mean increase in FEV1 reached up to 256 mL (p=0.033), with FeNO down 43% and EOS down 51%, and a half-life of up to 75 days supporting twice-yearly dosing; the Phase III part has been initiated.
Tag： SKB BIO06990.HKR&D Progress
21:17
[ ALEBUND-B (09637.HK): FDA Clears IND for First-in-class IgA Protease AP308 in IgA Nephropathy; First-in-human Trial to Commence ] On 8 September 2026, Alebund Pharmaceuticals (Jiangsu) Limited (09637.HK) announced in a voluntary announcement that the US FDA had approved the IND application for AP308, a first-in-class engineered recombinant IgA protease, to initiate a first-in-human clinical trial in IgA nephropathy; AP308 is believed to be the first IgA protease-based IgAN candidate approved for clinical trials, and the company holds global rights to the drug.
Tag： ALEBUND-B09637.HKClinical Trial
19:54
[ DELTON (01989.HK): Completes Registration of RMB 96 Million Capital Increase in Wholly-owned Subsidiary Huangshi Guanghe, Raising Registered Capital to RMB 876 Million ] On 8 September 2026, Delton Technology (Guangzhou) Inc. (01989.HK) announced that its RMB 96 million capital increase in wholly-owned subsidiary Huangshi Guanghe Precision Circuit Co., Ltd. using fund-raising proceeds had been completed, with the subsidiary's registered capital increased from RMB 780 million to RMB 876 million and a renewed business licence obtained.
Tag： DELTON01989.HKCapital increase
19:27
[ OOH HOLDINGS (08091.HK): Major Shareholder Silver Pro Sells 13.05% Stake at HKD 0.03 per Share, Exiting Completely ] On 8 September 2026, OOH Holdings Limited (08091.HK) announced that major shareholder Silver Pro Investments Limited had sold 93,960,000 shares (approximately 13.05%) to Mr. Leung Chun Wai, Mr. Yam Wai Shing and Mr. Yau Siu Yeung for a total consideration of HKD 2,818,800 (HKD 0.03 per share); after the sale Silver Pro holds no shares, while the three buyers hold approximately 8.47%, 2.62% and 4.28% respectively.
Tag： OOH HOLDINGS08091.HKReduction of Holdings
19:13
[ CN CULTURE GP (00745.HK): Subsidiary Chic Culture Signs MOU with Fireverse for Strategic Cooperation in AI Music Platforms, Artist Co-creation and Live Concerts ] On 8 September 2026, China National Culture Group Limited (00745.HK) announced that its indirect wholly-owned subsidiary Chic Culture had entered into a non-legally binding MOU with FIREVERSE Ventures for proposed strategic cooperation covering an AI-generated music content platform, artist discovery and AI co-creation, and live concerts and performance businesses; commercial terms are to be negotiated and finalised within three months, and the MOU does not constitute a discloseable or connected transaction.
Tag： CN CULTURE GP00745.HKstrategic cooperation
19:08
[ DEEPZERO (02723.HK) and BIDU-W (09888.HK): Qualify for Southbound Stock Connect and Fast-addition to HKEX Tech 100, Effective 14 September ] On 8 September 2026, DEEPZERO (02723.HK) and BIDU-W (09888.HK) were confirmed to qualify for Southbound trading under Stock Connect and meet the fast-addition criteria of the HKEX Tech 100 Index; the two stocks will be added to the HKEX Tech 100 Index and the HKEX Tech and US Tech 100 Index after the market close on 11 September 2026, with the changes effective 14 September 2026.
Tag： DEEPZERO02723.HKHKEX Tech 100
19:00
[ Youdi Robot (03231.HK): Grey-market Closing Price Soars 106.64% Ahead of Hong Kong Listing Tomorrow ] On 8 September 2026, Youdi Robot (03231.HK) was set to list on the Stock Exchange of Hong Kong on 9 September 2026 (Wednesday). Grey-market trading closed at HKD 29.860, up 106.64% from the offer price of HKD 14.45, implying a paper gain of about HKD 3,082 per board lot of 200 shares excluding fees.
Tag： Youdi Robot03231.HKGrey MarketIPO
18:53
[ HAIWEI ELEC (09609.HK): Subscribes RMB 20 Million for Approximately 0.28% Stake in Sungrow Hydrogen, Deepening Downstream Cooperation for Capacitor Films ] On 8 September 2026, Hebei Haiwei Electronic New Material Technology Co., Ltd. (09609.HK) announced that it had subscribed for 1,154,000 new shares of Sungrow Hydrogen Energy Technology Co., Ltd., a water-electrolysis hydrogen equipment maker and subsidiary of Sungrow Power Supply (300274), for RMB 20 million (approximately 0.2825% of enlarged capital), completed on 28 April 2026; after Sungrow Hydrogen's new financing round on 10 August 2026, its implied post-money valuation reached approximately RMB 7,223 million and the company's stake was diluted to approximately 0.2769%, with the investment not constituting a discloseable transaction.
Tag： HAIWEI ELEC09609.HKStrategic Investment
18:48
[ TEDA BIOMEDICAL (08189.HK): Signs Strategic Cooperation Framework Agreement with Xingchen Tongyong to Advance Integration of Healthcare LLMs and Embodied Intelligence ] On 8 September 2026, Tianjin TEDA Biomedical Engineering Company Limited (08189.HK) announced in a voluntary announcement the signing of a strategic cooperation framework agreement with Hunan Xingchen Tongyong Robot Co., Ltd., under which the parties will jointly build embodied intelligence scenario open centres and an innovation and application ecosystem, and promote the industrial application of an integrated healthcare large language model and embodied intelligence technology system.
Tag： TEDA BIOMEDICAL08189.HKstrategic cooperation
18:47
[ TEDA BIOMEDICAL (08189.HK): Controlling Subsidiary Yishu Jingcheng Signs Strategic Cooperation Agreement with China Communications Construction Group Design Institute on Public Data Operation and Industry LLMs ] On 8 September 2026, Tianjin TEDA Biomedical Engineering Company Limited (08189.HK) announced in a voluntary announcement that its controlling subsidiary Yishu Jingcheng had signed a strategic cooperation agreement with the Design Institute under central SOE China Communications Construction Group, to jointly develop and operate projects in public data operation and industry large language models, with Yishu Jingcheng providing full-process data services and the Design Institute contributing top-tier qualifications and large-project integration experience.
Tag： TEDA BIOMEDICAL08189.HKstrategic cooperation
18:33
[ MEIG (03268.HK): Wholly-owned Subsidiary to Subscribe RMB 30 Million into Venture Capital Fund Targeting IC Industry Chain ] On 8 September 2026, MeiG Smart Technology Co., Ltd. (03268.HK) announced that its wholly-owned subsidiary Meige Zhitou, as a limited partner, will subscribe RMB 30 million from its own funds into Suzhou Puhua Chenguang Venture Capital Partnership (Limited Partnership), representing approximately 2.84% of the total subscribed capital of RMB 1.057 billion; the fund focuses on the integrated circuit industry chain with a seven-year term, and the investment does not constitute a connected transaction or major asset restructuring and requires no board or shareholders' approval.
Tag： MEIG03268.HKFund Investment
18:31
[ ASCLETIS-B (01672.HK): Initiates US Phase I Study of Oral Amylin Receptor Agonist Peptide ASC36 for Obesity; Up to 13.2% Weight Loss in Non-human Primates ] On 8 September 2026, Ascletis Pharma Inc. (01672.HK) announced in a voluntary announcement that it had initiated a US Phase I study of ASC36 oral tablets, an oral amylin receptor agonist peptide, for obesity following FDA IND approval, marking its fourth peptide Phase I study this year; in non-human primates, once-daily dosing for seven days achieved up to 13.2% mean weight loss versus baseline, with steady-state absolute oral bioavailability of 6% to 8%.
Tag： ASCLETIS-B01672.HKR&D Progress
18:29
[ HOLLY FUTURES (03678.HK): Proposes Appointment of Liu Xiaoxing as Independent Non-executive Director to Replace Resigning Director ] On 8 September 2026, Holly Futures Co., Ltd. (03678.HK) announced the proposed appointment of Mr. Liu Xiaoxing as an independent non-executive director to succeed the resigning Mr. Zhang Hongfa; Mr. Liu is currently a professor, doctoral supervisor and head of the finance department at Southeast University's School of Economics and Management, and his appointment is subject to review by the Shenzhen Stock Exchange and approval at an extraordinary general meeting, with an annual fee of HKD 120,000 (after tax).
Tag： HOLLY FUTURES03678.HKBoard Change
18:27
[ MINIEYE (02431.HK): Chairman Liu Guoqing Increases H Share Holdings with Purchase of 100,000 Shares ] On 8 September 2026, Minieye Technology Co., Ltd. (02431.HK) announced in a voluntary announcement that chairman, executive director and general manager Dr. Liu Guoqing had purchased a total of 100,000 H shares on the open market at an average price of approximately HKD 2.5272 per share, raising his beneficial holding to 34,683,503 shares (approximately 7.8%), and approximately 17.57% together with his concert parties.
Tag： MINIEYE02431.HKShare Increase
18:25
[ SBP GROUP (01177.HK): Preclinical Data of Oral STAT6 Degrader TQH5528 Presented at ERS 2026 ] On 8 September 2026, Sino Biopharmaceutical Limited (01177.HK) announced in a voluntary announcement that preclinical data of TQH5528, an oral STAT6 degrader independently developed by subsidiary Chia Tai-Tianqing Pharmaceutical Group, had been presented at ERS 2026, showing picomolar-level STAT6 degradation superior to comparator KT-621, significant STAT6 downregulation after a single dose in non-human primates, and improved airway hyperresponsiveness in a humanised asthma mouse model, with in vivo safety studies ongoing.
Tag： SBP GROUP01177.HKR&D Progress
Previous1..6667 686970..576     576 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments